Rübsamen K, Hornberger W
Knoll AG, Ludwigshafen, Germany.
Thromb Haemost. 1996 Jul;76(1):105-10.
Cofactor-independent thrombin inhibitors as adjunctive treatment to thrombolysis have been found to enhance reperfusion and reduce the incidence of early reocclusion more effectively than heparins. However, all thrombin inhibitors presently available are rapidly cleared from the circulation which may cause rebound effects after cessation of treatment. To evaluate the effect of PEG-hirudin (LU 87981) a new, long acting derivative of hirudin as adjunctive treatment to rt-PA, a thrombotic occlusion of the carotid artery was induced in mongrel dogs by means of a copper coil. Vessel patency was continuously monitored with an electromagnetic flow probe. Thrombolysis of the occluded artery was induced by administration of 40 micrograms x kg-1 + 240 micrograms x kg-1 x h-1 rt-PA (low dose) or 80 micrograms x kg-1 + 480 micrograms x kg-1 x h1 rt-PA (high dose). With high dose rt-PA treatment, patency was achieved in all animals within 50 min (range 24 to 75), with low dose rt-PA treatment only in 6 out of 8 animals after 73 min (range 26 to 117). Concomitant administration of PEG-hirudin (0.3 mg x kg-1 bolus + 0.15 mg x kg-1 x h-1 infusion) increased the incidence of reperfusion in the low dose rt-PA group to 100% while the reperfusion time was shortened from 73 min in the corresponding control group to 38 min (range 20 to 75 min) in the group given PEG-hirudin (p = 0.065, Mann-Whitney U-test). The carotid artery blood flow, which rapidly declined to zero within 18 to 27 min after discontinuing low or high dose rt-PA infusions remained at a sustained level for the whole observation period of 4 h only in the group given PEG-hirudin. Only one animal reoccluded after 229 min. Unfractionated heparin (UFH) given at a dose of 0.3 mg x kg-1 bolus + 0.3 mg x kg-1 x h-1 infusion did not improve the incidence of reperfusion or lower the incidence of reocclusion. Buccal bleeding time was prolonged after high dose rt-PA treatment and after low dose rt-PA with adjunctive UFH- or PEG-hirudin treatment. Buccal blood loss was not significantly affected by either treatment. In conclusion, these experiments indicate that early reocclusion after thrombolysis can effectively be diminished by concomitant treatment with the long acting thrombin inhibitor PEG-hirudin with moderate effects on bleeding time and aPTT.
已发现,作为溶栓辅助治疗的非辅因子依赖性凝血酶抑制剂比肝素更能有效增强再灌注并降低早期再闭塞的发生率。然而,目前所有可用的凝血酶抑制剂都能迅速从循环中清除,这可能在治疗停止后引起反跳效应。为了评估水蛭素的一种新型长效衍生物聚乙二醇化水蛭素(LU 87981)作为rt-PA辅助治疗的效果,通过铜线圈在杂种犬中诱导颈动脉血栓形成。用电磁流量探头持续监测血管通畅情况。通过给予40微克·千克⁻¹ + 240微克·千克⁻¹·小时⁻¹ rt-PA(低剂量)或80微克·千克⁻¹ + 480微克·千克⁻¹·小时⁻¹ rt-PA(高剂量)诱导闭塞动脉的溶栓。采用高剂量rt-PA治疗时,所有动物在50分钟内(范围为24至75分钟)实现血管再通;采用低剂量rt-PA治疗时,8只动物中只有6只在73分钟后(范围为26至117分钟)实现血管再通。同时给予聚乙二醇化水蛭素(0.3毫克·千克⁻¹推注 + 0.15毫克·千克⁻¹·小时⁻¹输注)可使低剂量rt-PA组的再灌注发生率提高到100%,而再灌注时间从相应对照组的73分钟缩短至给予聚乙二醇化水蛭素组的38分钟(范围为20至75分钟)(曼-惠特尼U检验,p = 0.065)。在停止低剂量或高剂量rt-PA输注后18至27分钟内迅速降至零的颈动脉血流量,仅在给予聚乙二醇化水蛭素的组中在整个4小时观察期内保持在持续水平。只有一只动物在229分钟后发生再闭塞。给予剂量为0.3毫克·千克⁻¹推注 + 0.3毫克·千克⁻¹·小时⁻¹输注的普通肝素(UFH)并未改善再灌注发生率或降低再闭塞发生率。高剂量rt-PA治疗后以及低剂量rt-PA联合UFH或聚乙二醇化水蛭素治疗后,颊部出血时间延长。两种治疗对颊部失血量均无显著影响。总之,这些实验表明,通过与长效凝血酶抑制剂聚乙二醇化水蛭素联合治疗可有效减少溶栓后的早期再闭塞,对出血时间和活化部分凝血活酶时间(aPTT)有中度影响。